The useful question isn't "how is the gum category doing." It's "what jobs did people hire gum to do, and what does those jobs better now." Gum was always a bundle of unrelated jobs sold as one product. It didn't lose to a rival gum. It got disassembled, job by job.
The useful question is not "how is the gum category doing" but "what jobs did people hire gum to do, and what else can do those jobs now." Gum was always a bundle of unrelated jobs sold as one product.
When we said "the triggers eroded," we described the symptom. The mechanism is that each of those jobs got picked off by a separate, better-funded competitor that gum's makers don't even count as competition. The category didn't lose to a rival gum. It got disassembled job by job.
The single product that most directly inherited gum's core niche, discreet, oral, repeat-purchase, smoking-adjacent, bound to the same daily cues, is the nicotine pouch, Zyn above all. It occupies almost the exact behavioral slot: something small you park in your mouth, tied to the after-meal / driving / stressed / need-a-hit triggers, sold at checkout, consumed fast, bought constantly. And its trajectory is the inverse of gum's.
Zyn sold ~581M cans in the US in 2024 for about $1.88B net revenue, roughly half the entire US gum category, from a single brand.
It isn't that gum chewers switched to pouches one-for-one. It's that the smoking-substitute and oral-fixation jobs, which propped up a lot of gum volume, found a product that does them more potently. The same harm-reduction wave that should have helped gum (people quitting cigarettes) routed around it. You can't see that force from inside the gum aisle.
We described the M&A as strategy. The financial logic underneath: a declining category that still throws off cash is not run for growth, it's run for harvest. Stop investing in innovation, cut marketing, raise prices, let volume bleed, milk brand equity that's already paid for.
Dollars roughly flat while units fall means price is doing the work. That's the fingerprint of harvesting, not health.
This reframes the Perfetti purchase. Buying Mondelēz's developed-market gum at ~15× EBITDA is not a bet that gum comes back. It's a consolidation-and-cost bet: become the scale player in a shrinking category, strip duplicated overhead, run the brands for cash.
Mondelēz exited because a declining cash cow is a distraction inside a growth-chasing conglomerate. Perfetti (privately held, confectionery-focused) can run it patiently for yield. The category is quietly being reclassified from "growth asset" to "annuity," and the ownership reshuffle is that reclassification happening in public.
The deeper point behind "APAC growth" is product lifecycle by geography. In the developed West, gum is late-stage: habituated, saturated, declining. In much of Asia, Latin America and Africa it's early-stage, and it plays a different role, aspirational, novel, a small marker of Western-style disposable income rather than an ingrained habit.
Habit-based categories die a specific way: they fail to recruit a new cohort, then age out with their existing users. Gum's cues were transmitted socially and generationally, you saw adults chew, you associated it with driving, dating, work, smoking. Strip the cues from one generation and the next never forms the habit at all.
Gen Z preferring sour gummies isn't just a taste shift. It's a transmission failure.
A category with no loyalty moat and no new cohort is in slow liquidation regardless of what the incumbents do.
Gum's whole defensive repositioning is "sugar-free oral wellness", resting on sugar alcohols like xylitol and sorbitol, and on the dentist endorsement. That halo is now contestable. A Cleveland Clinic research team has published work associating the sugar alcohols erythritol and xylitol with elevated cardiovascular risk.
Higher circulating xylitol levels tracked with increased three-year risk of heart attack and stroke in an analysis of over 3,000 patients; intervention studies showed erythritol ingestion heightened platelet reactivity and clotting potential, an effect not seen with glucose.
The intervention arms were tiny (~20 healthy volunteers), so the findings may not hold at population scale, and xylitol is less common in US sugar-free products than abroad. This is not a settled verdict.
But the asymmetry is the point: gum migrated its survival strategy onto "healthier than candy," and that ground is no longer guaranteed solid. If the sugar-alcohol concern hardens, the one growth narrative the category has left (wellness, oral care, functional) takes the hit.
This ties straight back to the skeptic's instinct from the FAQ and Brief № 002: "thought to be safe" doing real work again. A category can't lean its whole turnaround on a health halo that a few hardening studies could puncture.
As gum fragments into functional gum, nicotine gum, CBD gum, caffeine gum, the line between "gum" and "oral delivery device" blurs, and different market-research firms count it differently. Some of the apparent decline in "gum" is real demand loss; some is reclassification as the interesting volume migrates into categories tracked separately.
When the numbers disagree wildly, the forecasts we saw ranged from flat to 4.7% CAGR, suspect definitional drift, not just analyst optimism. The thing being measured is quietly changing shape.
The blind spot is treating gum as a category. It's a bundle of jobs, each captured by a better competitor (pouches for oral fixation and smoking substitution, phones for idle time, energy drinks for alertness, mints and strips for breath), and what's left is being financially harvested in the West while quietly relocating to emerging markets, with its last defensive story (wellness) now exposed to a health reversal. None of that is visible from inside the gum aisle, which is exactly why it felt like something was missing.